Clifford Berger, MD
Interventional Cardiology · Boston, MANPI 1972569861
Payments from drug & device makers
Across 425 payments — averaging $397.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$78K
- Edwards Lifesciences$71K
- Boston Scientific$9K
- Atricure, Inc.$6K
- Abbott$1K
- E.r. Squibb & Sons, L.L.C.$848
- plus $3K from 26 others
Across 2 payments — averaging $950.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Atricure, Inc.$2K
What the payments were for
- Consulting fees$80,47595%
- Food & beverage$4,1305%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 132 | $78,366 |
| Edwards Lifesciences | 45 | $70,686 |
| Boston Scientific | 9 | $8,630 |
| Atricure, Inc. | 10 | $5,800 |
| Abbott | 6 | $1,276 |
| E.r. Squibb & Sons, L.L.C. | 33 | $848 |
| Novartis | 74 | $664 |
| Johnson & Johnson | 20 | $448 |
| Boehringer Ingelheim | 15 | $360 |
| Pfizer | 16 | $305 |
| AstraZeneca | 15 | $258 |
| Merck | 9 | $159 |
| Irhythm Technologies, Inc. | 1 | $139 |
| Novo Nordisk | 6 | $120 |
| Regeneron Healthcare Solutions, Inc. | 6 | $111 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $109 |
| Bardy Diagnostics, Inc. | 2 | $75 |
| Amgen | 3 | $61 |
| Bayer | 2 | $48 |
| Gilead | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $36 |
| Baxter Healthcare | 1 | $32 |
| Abiomed | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Shockwave Medical, Inc | 1 | $27 |
| Philips North America LLC | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNERGY$5,935
- CLINICAL TRIAL PRODUCT$2,635
- CardioMEMS HF System$1,000
- ZIO XT Patch$139
- ABSORB$100
How this compares
$168,790 in reported general payments places this provider in the 80th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 216 | $306,433 |
| Repatha SureclickEvolocumab | 65 | $74,819 |
| EntrestoSacubitril/Valsartan | 50 | $74,136 |
| JardianceEmpagliflozin | 14 | $18,795 |
| XareltoRivaroxaban | 11 | $13,190 |
| Ezetimibe | 152 | $8,355 |
| Rosuvastatin Calcium | 147 | $6,522 |
| Metoprolol Succinate | 279 | $5,989 |
| Atorvastatin Calcium | 350 | $5,881 |
| VascepaIcosapent Ethyl | 12 | $4,441 |
| Ranolazine ErRanolazine | 31 | $3,247 |
| Losartan Potassium | 168 | $1,734 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 94 | $1,644 |
| ClopidogrelClopidogrel Bisulfate | 91 | $1,337 |
| Nitroglycerin | 49 | $1,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $305 | $306,433216 claims |
| NovartisEntresto | $664 | $74,13650 claims |
| Boehringer IngelheimJardiance | $360 | $18,79514 claims |
| Johnson & JohnsonXarelto | $448 | $13,19011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 128 interventional cardiology providers in Massachusetts.
Other interventional cardiology in Boston
- Charles GibsonBoston$16.3M
- Eric SecemskyBoston$7.3M
- Duane PintoBoston$4.2M
- Suzanne BaronBoston$3.9M
- Pinak ShahBoston$3M
- Robert YehBoston$2.1M
- Jeffrey PopmaBoston$1.9M
- Roger LahamBoston$1.2M
- Farouc JafferBoston$900K
- Darshan DoshiBoston$838K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.